ParagonRx® | Minimize Risk and Optimize Use

WILMINGTON, Del.--(BUSINESS WIRE)--The practical aspects of utilizing a drug safety perspective in the development and implementation of Risk Evaluation and Mitigation Strategies (REMS) will be examined in a complimentary webinar for all interested parties this Wednesday, July 14, at 12 noon Eastern Time.

WILMINGTON, Del.--(BUSINESS WIRE)--ParagonRx, an inVentiv Health, Inc. company (Nasdaq: VTIV) and a leading consulting company specializing in pharmaceutical risk management and optimizing medication, has named William L. (Billy) Holden as chief safety officer. Holden has almost 20 years experience working at top levels for major drug companies in the areas of pharmacoepidemiology, signal detection and risk management.

WILMINGTON, DE, May 5, 2010 – The role of healthcare payers is increasingly becoming the focus in how FDA-mandated REMS – Risk Evaluation and Mitigation Strategies intended to increase safe drug use – are impacting the practice of medicine in the U.S., and that subject will be examined in an open webinar next Wednesday, May 12, at 12 noon Eastern Time.

WILMINGTON, DE, April 7, 2010 – The REMS Coordination Office (RCO) is the organizational hub for a pharmaceutical company's cross-functional Risk Evaluation and Mitigation Strategies (REMS) team, enabling the team to effectively manage REMS. This will be the topic of an open industry webinar at 12 noon EDT on Wednesday, April 14, sponsored by ParagonRx.

WILMINGTON, Del., March 5, 2010 /Business Wire/ -- Three pharmaceutical executives with extensive experience in dealing with the FDA’s Risk Evaluation and Mitigation Strategy (REMS) will share their thoughts and practices at an open industry webinar at 12 noon EST on Wednesday, March 10, sponsored by ParagonRx.

An open industry webinar at 12 noon EST on Wednesday, February 10, entitled " Beginning with the End in Mind: Managing the Lifecycle of REMS Implementation".  It is the third in a series of monthly "Wednesday FoREMS" webinars sponsored by ParagonRx, an inVentiv Health company (Nasdaq: VTIV) and a leading consulting company specializing in pharmaceutical risk management and optimizing medication.

SOMERSET, N.J., Jan. 5, 2010 (GLOBE NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV), a leading provider of commercialization services to the global healthcare industries, today announced it has acquired ParagonRx, a leading consulting company specializing in pharmaceutical risk management and optimizing medication use. The addition of ParagonRx will position inVentiv as the leading provider of comprehensive, fully-integrated REMS (Risk Evaluation & Mitigation Strategy) and risk management solutions, ranging from strategic consulting and program design to implementation coordination, project tracking and assessment. The acquisition was completed on December 31, 2009.

Wilmington, DE, October 09, 2009 --(PR.com)-- Advisory to Medical Editors & Writers: Recently, the FDA issued a very important draft guidance for pharmaceutical and biotechnology companies for formatting, assessing and modifying Risk Evaluation Mitigation Strategies (REMS) to ensure the safe use of pharmaceutical products. Experts are now reviewing and interpreting this draft FDA guidance in a series of blogs.

WILMINGTON, Del., Oct. 1 /PRNewswire/ -- Yesterday, the FDA issued very important draft guidance for pharmaceutical and biotechnology companies for formatting, assessing and modifying Risk Evaluation & Mitigation Strategies (REMS) to ensure the safe use of pharmaceutical products.

WILMINGTON, Del., Sept. 30 /PRNewswire/ -- ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, has named Ellen M. Derrico as its chief marketing executive in a move to expand the company's market development.

WILMINGTON, Del., Sept. 14 /PRNewswire/ -- The airline and pharmaceutical industries both provide products and services that benefit mankind but which also can be dangerous if the risks are not properly calculated and dramatically lessened - but can drug manufacturers really learn from the experience of people who make and fly airplanes?